U.S. Markets closed

Analyzing Alexion Pharmaceuticals’ Operational Performance

Kenneth Smith
Analyzing Alexion Pharmaceuticals’ Operational Performance

This increase was attributable to higher professional services, asset-related charges, and charitable contributions. During the second quarter, Alexion incurred $803.7 million in acquired in-process research and development expenses related to its acquisition of Wilson Therapeutics. While Alexion had generated an operating income of $226.7 million in the second quarter of 2017, in the second quarter of 2018, it incurred an operating loss of $400.1 million.